Mimi Lo
Overview
Explore the profile of Mimi Lo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Vo K, Guan T, Banerjee R, Lo M, Young R, Shah N
J Oncol Pharm Pract
. 2022 Jan;
28(5):1244-1248.
PMID: 35084252
Introduction: Plasma cell leukemia (PCL) is a rare but aggressive variant of multiple myeloma (MM) with a poor prognosis. Due to the limited number of prospective clinical trials studying PCL,...
12.
Banerjee R, Huang C, Dunn L, Knoche J, Ryan C, Brassil K, et al.
JMIR Form Res
. 2022 Jan;
6(3):e33701.
PMID: 35039279
Background: For patients with multiple myeloma receiving high-dose chemotherapy followed by autologous stem cell transplantation (SCT), acute life disruptions and symptom burden may lead to worsened quality of life (QOL)...
13.
Banerjee R, Lo M, Klein L, Aras M, Logan A
J Oncol Pharm Pract
. 2021 Nov;
28(3):729-732.
PMID: 34846217
Introduction: For young adult patients with acute leukemia, both the efficacy and cardiotoxicity of anthracycline-based regimens have been documented. We report the case of a patient with severe cardiomyopathy, mechanically...
14.
Lee A, Oley Jr F, Lo M, Fong R, McGann M, Saunders I, et al.
Thromb Res
. 2021 Nov;
208:148-155.
PMID: 34798446
Introduction: Patients with central nervous system malignancies have limited representation in studies evaluating DOACs for VTE treatment. This study evaluated the safety and efficacy of DOACs in comparison with LMWH...
15.
Tam A, Jung Y, Young R, Huang C, Wolf J, Shah N, et al.
J Oncol Pharm Pract
. 2021 Oct;
28(8):1819-1825.
PMID: 34647506
Introduction: Subcutaneous daratumumab is non-inferior to intravenous daratumumab for the treatment of multiple myeloma and significantly reduced incidence of systemic reactions. However, manufacturer for subcutaneous daratumumab has not provided guidance...
16.
Banerjee R, Lo M, Martin 3rd T
Future Oncol
. 2021 Sep;
17(35):4849-4860.
PMID: 34553603
The treatment of relapsed multiple myeloma remains challenging. Based on interim data from the randomized Phase III IKEMA study demonstrating a progression-free survival benefit with a combination of isatuximab (Isa,...
17.
Kambhampati S, Sheng Y, Huang C, Bylsma S, Lo M, Kennedy V, et al.
Blood Adv
. 2021 Sep;
6(7):2045-2054.
PMID: 34543400
B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy (BCMA CAR-T) is an effective treatment of relapsed refractory multiple myeloma (MM). However, the pattern of infectious complications is not well elucidated....
18.
Gilreath J, Lo M, Bubalo J
Drugs
. 2021 Jun;
81(11):1285-1305.
PMID: 34160821
The thrombopoietin receptor agonists (TPO-RAs) romiplostim, eltrombopag, avatrombopag, and lusutrombopag carry unique US Food and Drug Administration (US FDA)- and European Medicines Agency (EMA)-approved indications and may be used to...
19.
Sugidono M, Lo M, Young R, Rosario K, Jung Y, Huang C, et al.
Transplant Cell Ther
. 2021 Apr;
27(4):344.e1-344.e5.
PMID: 33836888
Polypharmacy is common in older adults with cancer, but there is little evidence evaluating the impact of polypharmacy and other medication hazards on allogeneic hematopoietic cell transplantation (alloHCT) outcomes. A...
20.
Banerjee R, Marsal J, Huang C, Lo M, Thiruvengadam S, Kennedy V, et al.
Transplant Cell Ther
. 2021 Apr;
27(6):477.e1-477.e7.
PMID: 33831353
Preemptive administration of tocilizumab (toci) to manage cytokine release syndrome (CRS) after chimeric antigen receptor T cell (CAR-T) therapy may reduce rates of serious CRS but conversely may worsen neurotoxicity...